Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo
Oliver G. McDonald, … , Mark H. Hoofnagle, Gary K. Owens
Oliver G. McDonald, … , Mark H. Hoofnagle, Gary K. Owens
Published January 4, 2006
Citation Information: J Clin Invest. 2006;116(1):36-48. https://doi.org/10.1172/JCI26505.
View: Text | PDF
Research Article Genetics

Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo

  • Text
  • PDF
Abstract

Precise control of SMC transcription plays a major role in vascular development and pathophysiology. Serum response factor (SRF) controls SMC gene transcription via binding to CArG box DNA sequences found within genes that exhibit SMC-restricted expression. However, the mechanisms that regulate SRF association with CArG box DNA within native chromatin of these genes are unknown. Here we report that SMC-restricted binding of SRF to murine SMC gene CArG box chromatin is associated with patterns of posttranslational histone modifications within this chromatin that are specific to the SMC lineage in culture and in vivo, including methylation and acetylation to histone H3 and H4 residues. We found that the promyogenic SRF coactivator myocardin increased SRF association with methylated histones and CArG box chromatin during activation of SMC gene expression. In contrast, the myogenic repressor Kruppel-like factor 4 recruited histone H4 deacetylase activity to SMC genes and blocked SRF association with methylated histones and CArG box chromatin during repression of SMC gene expression. Finally, we observed deacetylation of histone H4 coupled with loss of SRF binding during suppression of SMC differentiation in response to vascular injury. Taken together, these findings provide novel evidence that SMC-selective epigenetic control of SRF binding to chromatin plays a key role in regulation of SMC gene expression in response to pathophysiological stimuli in vivo.

Authors

Oliver G. McDonald, Brian R. Wamhoff, Mark H. Hoofnagle, Gary K. Owens

×

Figure 7

SRF binding to CArG box chromatin is disrupted during SMC phenotypic switching.

Options: View larger image (or click on image) Download as PowerPoint
SRF binding to CArG box chromatin is disrupted during SMC phenotypic swi...
(A) Left: Expression of myocardin and KLF4 in response to PDGF-BB (BB) treatment of cultured SMCs for 24 hours (24hBB) or vehicle treatment for 24 hours (24hVeh). Right: Similar data from cells treated with PDGF-BB for 72 hours (72hBB) or cells treated with PDGF-BB media for 24 hours, followed by replacement of PDGF-BB media with vehicle media and incubation for 48 hours (24hBB48hVeh). Data were normalized to expression of 18S. PDGF-BB treatments were performed as described previously (8). (B) SMCs were treated with vehicle (Veh) or PDGF-BB for 24 hours, and SRF immunoprecipitates were subjected to Western blotting for H3K4dMe or SRF (IP control). (C) SMCs were treated with PDGF-BB as in A, mRNA was measured by RT-PCR as in A (top panel), and ChIP was performed at the 5′-CArG regions with the indicated genes for the indicated parameters (SRF binding, etc). (D) Rats were injured with balloon catheter as described in Methods, and mRNA or chromatin was isolated and analyzed by real-time RT-PCR and ChIP, respectively. The top panel is a histological display of uninjured control aorta (Sham) and an injured aorta (Injured), demonstrating that the balloon catheter injury technique employed successfully injured the vessels, as indicated by the presence of a neointima (NI) 14 days after injury. M refers to the position of the vessel media. For mRNA and ChIP (bottom panels), vessels were harvested 24 hours or 72 hours after injury and compared with control vessels.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts